Notably, the downregulation of Rgs2 is significantly associated with the recurrence and metastasis of CRC, and diminished expression of Rgs2 serves as a prognostic marker for reduced survival rates.[35] However, the extent to which Rgs2+CD8+ T cells possess these capabilities in MSS‐CRLM remains further investigated. This evidence concerns the gene RGS2 and colorectal carcinoma.